Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis

Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis

BackgroundThe pathological progression from liver injury to fibrosis is a hallmark of liver disease, with no effective strategies to halt this transition. Ginsenoside Rg1 has demonstrated a range of hepatoprotective properties; however, systematic preclinical evidence supporting its therapeutic pote...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lijuan Dan, Xiuyan Li, Shuanglan Chen, Xiaojie You, Dong Wang, Tianyuan Wang, Jia Li, Wenping Liu, Jie Mu, Quansheng Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pharmacology
Subjects:	ginsenoside Rg1 liver injury liver fibrosis preclinical evidence meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1512184/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ginsenoside Rg1: A bioactive therapeutic agent for diverse liver diseases
by: Mingyu Wu, et al.
Published: (2025-02-01)

Role of ginsenoside Rg1 as a PPAR-γ activator in protecting against manganese-induced hepatotoxicity: Insights into the TLR4/MyD88/MAPK signaling pathway
by: Mengjing Zhao, et al.
Published: (2025-01-01)

A novel strategy for the protective effect of ginsenoside Rg1 against ovarian reserve decline by the PINK1 pathway
by: Pengdi Yang, et al.
Published: (2025-12-01)

Ginsenoside Rg1 alleviates chronic testicular damage caused by cranial irradiation through the SCF/PI3K/Akt/mTOR pathway in mice
by: Qiuhua Zhou, et al.
Published: (2025-02-01)

Targeting and reprogramming microglial phagocytosis of neutrophils by ginsenoside Rg1 nanovesicles promotes stroke recovery
by: Kaichao Hu, et al.
Published: (2025-05-01)

Ginsenosides Rg1, Rb1 and rare ginsenosides: Promising candidate agents for Parkinson's disease and Alzheimer's disease and network pharmacology analysis
by: Mingchun Jiang, et al.
Published: (2025-02-01)

Ginsenosides 20R-Rg3 and Rg5 enriched black ginseng inhibits colorectal cancer tumor growth by activating the Akt/Bax/caspase-3 pathway and modulating gut microbiota in mice
by: Peng Yu, et al.
Published: (2025-01-01)

Ginsenoside Rd protects against acute liver injury by regulating the autophagy NLRP3 inflammasome pathway
by: Xiaomei Zhong, et al.
Published: (2025-01-01)

SOX9: a key transcriptional regulator in organ fibrosis
by: Yishuo Li, et al.
Published: (2025-02-01)

The Effect of FOXA3 Overexpression on Hepatocyte Differentiation and Liver Regeneration in a Fah cKO Mouse ModelSummary
by: Shao Li, et al.
Published: (2025-01-01)

Quantitative ultrasound rating of liver fibrosis in children with cystic fibrosis
by: G. M. Dvoryakovskaya, et al.
Published: (2014-08-01)

Progress and prospects of elastography techniques in the evaluation of fibrosis in chronic liver disease
by: Yang Wang, et al.
Published: (2024-04-01)

The role of the interleukin family in liver fibrosis
by: Zixin Zhang, et al.
Published: (2025-02-01)

Comparative analysis of physicochemical properties, ginsenosides content and α-amylase inhibitory effects in white ginseng and red ginseng
by: Huairui Wang, et al.
Published: (2023-01-01)

Non-invasive of liver fibrosis diagnostics: the role of serum markers
by: A. F. Sheptulina, et al.
Published: (2015-05-01)

The fibrosis-4 index and its association with carotid atherosclerosis in type 2 diabetes: a cross-sectional study in China
by: Ying Miao, et al.
Published: (2025-01-01)

Association Between Liver Fibrosis and Risk of Incident Stroke and Mortality: A Large Prospective Cohort Study
by: Zijie Wang, et al.
Published: (2025-02-01)

Gene therapy by hepatocyte growth factor results in regression of experimental liver fibrosis
by: N. A. Dzhoyashvili, et al.
Published: (2010-08-01)

Correlation between liver fibrosis in non-alcoholic fatty liver disease and insulin resistance indicators: a cross-sectional study from NHANES 2017–2020
by: Bo Yang, et al.
Published: (2025-01-01)

Liver Elastography for Liver Fibrosis Stratification: A Comparison of Three Techniques in a Biopsy-Controlled MASLD Cohort
by: Antonio Liguori, et al.
Published: (2025-01-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Experimental Validation of Antiobesogenic and Osteoprotective Efficacy of Ginsenoside CK via Targeting Lipid and Atherosclerosis Pathways
by: Md. Niaj Morshed, et al.
Published: (2024-12-01)

Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
by: Qiyao Wei, et al.
Published: (2025-02-01)

Collagen fibers quantification for liver fibrosis assessment using linear dichroism photoacoustic microscopy
by: Yang Qiu, et al.
Published: (2025-04-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

Changes in DNA methylation profile in liver tissue during progression of HCV-induced fibrosis to hepatocellular carcinoma
by: I. A. Goncharova, et al.
Published: (2023-03-01)

Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Zhifeng Gao, et al.
Published: (2025-01-01)

The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
by: Xue Wang, et al.
Published: (2025-01-01)

Prevalence and risk factors of liver fibrosis in patients with metabolic-associated fatty liver disease undergoing bariatric surgery
by: Amr Elsayed, et al.
Published: (2024-12-01)

Liver macrophage-derived exosomal miRNA-342-3p promotes liver fibrosis by inhibiting HPCAL1 in stellate cells
by: Wenshuai Li, et al.
Published: (2025-02-01)

Evaluation of liver fibrosis in HCV-infected patients using two-dimensional shear-wave elastography (2D-SWE) before and after antiviral treatment
by: Inglot Marcin, et al.
Published: (2024-12-01)

Pathological Microenvironment‐Remodeling Nanoparticles to Alleviate Liver Fibrosis: Reversing Hepatocytes‐Hepatic Stellate Cells Malignant Crosstalk
by: Ling‐Feng Zhang, et al.
Published: (2025-01-01)

Baseline liver fibrosis-4 score correlates to the progression of anxiety and cognitive impairment in patients with Parkinson’s disease
by: Yongqing Cheng, et al.
Published: (2025-01-01)

Clostridium Scindens Protects Against Vancomycin‐Induced Cholestasis and Liver Fibrosis by Activating Intestinal FXR‐FGF15/19 Signaling
by: Jintao Xiao, et al.
Published: (2025-02-01)

A machine learning based algorithm accurately stages liver disease by quantification of arteries
by: Zhengxin Li, et al.
Published: (2025-01-01)

Ginsenoside Rk2 alleviates hepatic ischemia/reperfusion injury by enhancing AKT membrane translocation and activation
by: Hong Shen, et al.
Published: (2025-01-01)

Cellular and immune landscape of chronic liver diseases: insights from immunophenotyping
by: Shaghayegh Soleimani, et al.
Published: (2025-01-01)

Evaluating the antifibrotic potential of naringenin, asiatic acid, and icariin using murine and human precision‐cut liver slices
by: Ke Luo, et al.
Published: (2024-11-01)

Association of liver fibrosis with aneurysm size and mortality risk in patients undergoing open abdominal aortic aneurysm repair
by: Mohamad Jamalinia, et al.
Published: (2025-01-01)

Association between mixed exposure of non-persistent pesticides and liver fibrosis in the general US population: NHANES 2013–2016
by: Shuge Shu, et al.
Published: (2025-01-01)